CSIMarket
 


Quidelortho Corp  (QDEL)
Other Ticker:  
 

Quidelortho's Long Term Debt to Equity

QDEL's quarterly Long Term Debt to Equity and Long Term Debt, Equity growth


Due to long-term debt repayement of -1.47% Quidelortho improved Long Term Debt to Equity in third quarter 2023 to 0.46, above the Quidelortho's average Long Term Debt to Equity.

Within In Vitro & In Vivo Diagnostic Substances industry in the third quarter 2023, 3 other companies have achieved lower Long Term Debt to Equity than Quidelortho in the III Quarter 2023. While Long Term Debt to Equity total ranking has deteriorated compared to the second quarter 2023 from 966 to 1258 .

Explain Long Term Debt to Equity Ratio?
How much Long Term Debt QDELīs has?
What is the structure of QDELīs Equity?


QDEL Long Term Debt to Equity (Oct 01 2023)
III. Quarter
(Jul 02 2023)
II. Quarter
(Apr 02 2023)
I. Quarter
(Jan 01 2023)
IV. Quarter
(Oct 02 2022)
III. Quarter
Y / Y Equity Change 3.57 % 1.69 % 106.9 % 155.76 % 193.46 %
Y / Y Long Term Debt Change -8.36 % -8.87 % - - -
Long Term Debt to Equity MRQ 0.46 0.46 0.48 0.49 0.52
QDEL's Total Ranking # 1258 # 966 # 1243 # 1149 # 0
Seq. Equity Change -0.72 % 0.12 % 1.25 % 2.9 % -2.53 %
Seq. Long Term Debt Change -1.47 % -2.99 % -2.11 % -2.06 % -2.03 %



Long Term Debt to Equity third quarter 2023 Company Ranking
Within: No.
In Vitro & In Vivo Diagnostic Substances Industry # 4
Healthcare Sector # 166
Overall Market # 1258


Long Term Debt to Equity Statistics
High Average Low
1.66 0.42 0.02
(Dec 31 2017)   (Sep 30 2014)




Financial Statements
Quidelortho's Equity $ 4,967 Millions Visit QDEL's Balance sheet
Quidelortho's Long Term Debt $ 2,275 Millions Visit QDEL's Balance sheet
Source of QDEL's Sales Visit QDEL's Sales by Geography


Cumulative Quidelortho's Long Term Debt to Equity

QDEL's Long Term Debt to Equity for the trailling 12 Months

QDEL Long Term Debt to Equity

(Oct 01 2023)
III. Quarter
(Jul 02 2023)
II. Quarter
(Apr 02 2023)
I. Quarter
(Jan 01 2023)
IV. Quarter
(Oct 02 2022)
III. Quarter
Y / Y Equity TTM Growth 3.57 % 1.69 % 106.9 % 155.76 % 193.46 %
Y / Y Long Term Debt TTM Growth -8.36 % -8.87 % - - -
Long Term Debt to Equity TTM 0.47 0.49 0.5 0.44 0.36
Total Ranking TTM # 1431 # 108 # 1406 # 42 # 0
Seq. Equity TTM Growth -0.72 % 0.12 % 1.25 % 2.9 % -2.53 %
Seq. Long Term Debt TTM Growth -1.47 % -2.99 % -2.11 % -2.06 % -2.03 %


On the trailing twelve months basis Due to long-term debt repayement of -1.47% Quidelortho decreased Long Term Debt to Equity in the 12 months ending in III Quarter 2023 to 0.47, above the Quidelortho's average Long Term Debt to Equity.
Long Term Debt to Equity is the average cumulative value over the last four quarters.

Among companies in the In Vitro & In Vivo Diagnostic Substances industry 3, during the past 12 months, other companies have achieved lower Long Term Debt to Equity than Quidelortho. While Long Term Debt to Equity total ranking has deteriorated during the twelve months ending in the III Quarter 2023, compared to the prior period, from 108 to 1431.

Explain Long Term Debt to Equity Ratio?
How much Long Term Debt QDELīs has?
What is the structure of QDELīs Equity?

TTM Long Term Debt to Equity Company Ranking
Within: No.
Within the In Vitro & In Vivo Diagnostic Substances Industry # 4
Healthcare Sector # 228
Within the Market # 1431


trailing twelve months Long Term Debt to Equity Statistics
High Average Low
0.94 0.34 0.01
(Dec 31 2017)   (Mar 31 2020)




Companies with similar Long Term Debt to Equity in the quarter ending Oct 01 2023, within In Vitro & In Vivo Diagnostic Substances Industry Long Term Debt to EquityOct 01 2023 MRQ Long Term DebtOct 01 2023 MRQ Equity
Lantheus Holdings Inc   0.80 $ 560.576  Millions$ 698.759  Millions
Idexx Laboratories Inc  0.48 $ 618.813  Millions$ 1,297.407  Millions
Quidelortho Corp  0.46 $ 2,274.600  Millions$ 4,966.700  Millions
Immucell Corp  0.42 $ 10.905  Millions$ 26.013  Millions
Neogen Corporation  0.28 $ 886.177  Millions$ 3,146.175  Millions
Alpha Teknova Inc   0.13 $ 13.168  Millions$ 99.652  Millions

Date modified: 2023-11-03T20:15:38+00:00



Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright Đ 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com